Zhijiang Biotech announced that the company's human papillomavirus nucleic acid typing test kit recently obtained a national Class III medical device registration certificate. The registration certificate is valid from July 29, 2026 to July 28, 2031. The product can detect 23 types of HPV, covering mainstream high-risk and low-risk types, and is suitable for use in China and countries and regions that have approved NMPA. Product certification will enrich the company's product range and enhance competitiveness in the field of HPV testing, but there are risks such as product competition and uncertain profit impacts, which reminds investors to pay attention.

Zhijiang Biotech announced that the company's human papillomavirus nucleic acid typing test kit recently obtained a national Class III medical device registration certificate. The registration certificate is valid from July 29, 2026 to July 28, 2031. The product can detect 23 types of HPV, covering mainstream high-risk and low-risk types, and is suitable for use in China and countries and regions that have approved NMPA. Product certification will enrich the company's product range and enhance competitiveness in the field of HPV testing, but there are risks such as product competition and uncertain profit impacts, which reminds investors to pay attention.